EGFR敏感突变PD-L1阳性晚期非小细胞肺癌治疗的研究进展

Progress in Treatment of Advanced Non-small Cell Lung Cancer with EGFR Sensitive Mutation and PD-L1 Positive Expression

临床前研究表明表皮生长因子受体(epidermal growth factor receptor,EGFR)酪氨酸激酶抑制剂和免疫检查点抑制剂可以协同消灭肿瘤细胞。有EGFR敏感突变同时程序性死亡-配体1(programmed cell death-ligand 1,PD-L1)阳性表达的非小细胞肺癌(non-small cell lung cancer,NSCLC)患者可能是低毒高效的靶向药物联合免疫治疗的最佳受益者。该文从临床医生的角度,关注晚期EGFR敏感突变且有PD-L1阳性表达的NSCLC亚组患者。根据目前的临床证据,该文从诸多前瞻性临床试验结果到未来发展方向进行阐述,给临床治疗提供参考。

Preclinical studies have indicated that epidermal growth factor receptor(EGFR)tyrosine kinase inhibitors(TKIs)combined with immune checkpoint inhibitors(ICIs)can synergistically kill cancer cells.Therefore,it seems that advanced non-small cell lung cancer(NSCLC)patients with both EGFR sensitive mutation and programmed cell death-ligand1(PD-L1)positive expression may achieve greater benefits from these two low-toxicity and high-efficacy therapies.In this review the progress in treatment of this special group of patients based on the current evidence from the prospective clinical studies are elaborated,and the therapeutic strategies and related new drug development are discussed.